• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Research Brief on 1-Methyl-4-(1-methylpyrazol-4-yl)pyrazole (CAS: 40534-39-2): Recent Advances and Applications

1-Methyl-4-(1-methylpyrazol-4-yl)pyrazole (CAS: 40534-39-2) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile applications in drug discovery and development. Recent studies have highlighted its potential as a key scaffold in the design of novel therapeutic agents, particularly in the areas of oncology, neurology, and infectious diseases. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and mechanistic insights.

One of the most notable advancements in the study of 1-Methyl-4-(1-methylpyrazol-4-yl)pyrazole is its role as a selective kinase inhibitor. Kinases are critical targets in cancer therapy, and recent research has demonstrated that this compound exhibits potent inhibitory activity against specific kinases involved in tumor proliferation and metastasis. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported that derivatives of this compound showed promising efficacy in preclinical models of breast cancer, with minimal off-target effects. The study also elucidated the compound's binding mode through X-ray crystallography, providing valuable insights for further optimization.

In addition to its anticancer properties, 1-Methyl-4-(1-methylpyrazol-4-yl)pyrazole has been investigated for its potential in treating neurodegenerative disorders. A recent study in ACS Chemical Neuroscience revealed that this compound can modulate the activity of certain neurotransmitter receptors, offering a potential therapeutic avenue for conditions such as Alzheimer's disease and Parkinson's disease. The researchers employed a combination of in vitro assays and computational modeling to identify the compound's interaction with key neuronal targets, paving the way for future drug development efforts.

Another area of interest is the compound's application in antimicrobial therapy. With the rise of antibiotic-resistant pathogens, there is an urgent need for new antimicrobial agents. A 2022 study in Bioorganic & Medicinal Chemistry Letters demonstrated that 1-Methyl-4-(1-methylpyrazol-4-yl)pyrazole derivatives exhibit broad-spectrum activity against both Gram-positive and Gram-negative bacteria. The study also highlighted the compound's ability to disrupt bacterial biofilm formation, a critical factor in chronic infections. These findings suggest that this compound could serve as a promising lead for the development of next-generation antibiotics.

The synthesis of 1-Methyl-4-(1-methylpyrazol-4-yl)pyrazole and its derivatives has also seen significant progress in recent years. Advances in green chemistry and catalytic methods have enabled more efficient and sustainable production of this compound. For example, a 2023 publication in Organic Process Research & Development described a novel catalytic protocol that reduces the need for hazardous reagents and minimizes waste generation. Such innovations are crucial for scaling up production while adhering to environmental and safety regulations.

In conclusion, 1-Methyl-4-(1-methylpyrazol-4-yl)pyrazole (CAS: 40534-39-2) represents a multifaceted compound with diverse applications in medicinal chemistry. Its potential as a kinase inhibitor, neuroprotective agent, and antimicrobial candidate underscores its importance in contemporary drug discovery. Future research should focus on optimizing its pharmacokinetic properties and evaluating its efficacy in clinical trials. The continued exploration of this compound and its derivatives holds great promise for addressing unmet medical needs across various therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)